GlaxoSmithKline : Une nouvelle année de transition impactée par la COVID-19
>Un T4 qui ne peut être extrapolé pour ce S1 - Alors que nous espérions un point bas obtenu cette année, le manque de visibilité du fait de la pandémie et les investissements en R&D conduisent le groupe à de nouveau prévoir une année de décroissance. La fin d’année 2020 ne pose cependant que peu de questions. Le T4 est même de bonne facture, 1% au-dessus des attentes sur le CA et 1% au-dessus du BPA attendu. Comme nous l’anticipions, « Established drugs » et le Consum...GlaxoSmithKline is a global healthcare company. Co.'s segments include: Pharmaceuticals; Vaccines; and Consumer Healthcare. The Pharmaceuticals segment is focused on developing new medicines in respiratory, HIV, oncology and immuno-inflammation, with discovery research exploring these and other areas. The Vaccines segment has a portfolio and pipeline of vaccines to help protect people throughout life. Co. delivers vaccines to people living in over 160 countries. The Consumer Healthcare segment develops and markets consumer-preferred brands in oral health, pain relief, respiratory, nutrition/gastro-intestinal and skin health.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.